| Literature DB >> 34166845 |
Theo Gülen1, Cem Akin2, Patrizia Bonadonna3, Frank Siebenhaar4, Sigurd Broesby-Olsen5, Knut Brockow6, Marek Niedoszytko7, Boguslaw Nedoszytko8, Hanneke N G Oude Elberink9, Joseph H Butterfield10, Wolfgang R Sperr11, Ivan Alvarez-Twose12, Hans-Peter Horny13, Karl Sotlar14, Juliana Schwaab3, Mohamad Jawhar15, Roberta Zanotti16, Gunnar Nilsson17, Jonathan J Lyons18, Melody C Carter18, Tracy I George19, Olivier Hermine20, Jason Gotlib21, Alberto Orfao22, Massimo Triggiani23, Andreas Reiter15, Karin Hartmann24, Mariana Castells25, Michel Arock26, Lawrence B Schwartz27, Dean D Metcalfe18, Peter Valent11.
Abstract
In recent years, knowledge about mechanisms underlying mast cell activation (MCA) and accumulation in various pathologic conditions increased substantially. In addition, criteria and a classification of MCA syndromes (MCASs) have been set forth. MCAS is defined by typical clinical symptoms, a substantial increase in serum tryptase level during an attack over the patient's baseline tryptase, and a response of the symptoms to drugs targeting mast cells, mediator production, and/or mediator effects. Alternative diagnostic criteria of MCAS have also been suggested, but these alternative criteria often lack specificity and validation. In this report, we critically review the contemporary literature relating to MCAS and compare the specificity, sensitivity, and strength of MCAS-related parameters within proposals to diagnose and classify MCAS and its variants. Furthermore, we highlight the need to apply specific consensus criteria in the evaluation and classification of MCAS in individual patients. This is an urgent and important medical necessity because as an increasing number of patients are being given a misdiagnosis of MCAS based on nonspecific criteria, which contributes to confusion and frustration by patients and caregivers and sometimes may delay recognition and treatment of correct medical conditions that often turn out to be unrelated to MCA.Entities:
Keywords: Anaphylaxis; Hereditary alpha Tryptasemia; MCAS; Mast cells; Mastocytosis; Tryptase; Vienna consensus criteria
Mesh:
Substances:
Year: 2021 PMID: 34166845 DOI: 10.1016/j.jaip.2021.06.011
Source DB: PubMed Journal: J Allergy Clin Immunol Pract